Point72 Hong Kong’s Nektar Therapeutics NKTR Stock Holding History

Point72 Hong Kong’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-201	Closed	-$10K	–	1151
2022 Q3	$10K	Buy	+201	New	+$12K	﹤0.01%	1719
2021 Q4	–	Sell	-350	Closed	-$94K	–	2220
2021 Q3	$94K	Sell	350 -707	-67%	-$170K	﹤0.01%	1362
2021 Q2	$272K	Buy	+1,057	New	+$293K	0.01%	1075
2021 Q1	–	Sell	-9	Closed	-$2K	–	2084
2020 Q4	$2K	Buy	+9	New	+$2.33K	﹤0.01%	1649
2020 Q3	–	Sell	-1,409	Closed	-$489K	–	1412
2020 Q2	$489K	Buy	+1,409	New	+$440K	0.05%	343
2019 Q4	–	Sell	-481	Closed	-$132K	–	1361
2019 Q3	$132K	Buy	+481	New	+$176K	0.04%	393
2019 Q2	–	Sell	-15	Closed	-$7K	–	1311
2019 Q1	$7K	Buy	+15	New	+$8.89K	﹤0.01%	789
2018 Q4	–	Sell	-11	Closed	-$10K	–	1104
2018 Q3	$10K	Buy	+11	New	+$9.39K	﹤0.01%	664
2018 Q2	–	Sell	-13	Closed	-$21K	–	1099
2018 Q1	$21K	Buy	+13	New	+$16.7K	0.01%	614
2016 Q4	–	Sell	-27	Closed	-$7K	–	983
2016 Q3	$7K	Buy	+27	New	+$6.95K	﹤0.01%	669

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Hong Kong's NKTR Position: Q4 2022 in Review

Point72 Hong Kong sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 201 shares — an estimated $10K sold.

Point72 Hong Kong first reported a position in NKTR in Q3 2016 and held it in 10 quarters. The position peaked at $489K in Q2 2020. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Point72 Hong Kong reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 201 Nektar Therapeutics shares in Q4 2022, an estimated $10K.
Point72 Hong Kong first reported a position in Nektar Therapeutics in Q3 2016 and held it in 10 quarters.
Point72 Hong Kong's Nektar Therapeutics position peaked at $489K in Q2 2020.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.